1. Home
  2. Analysis
  3. Microangiopathic-haemolytic-anaemia

Microangiopathic haemolytic anaemia: treatments, associated drugs and conditions

Summary:

Microangiopathic haemolytic anaemia: anaemia due to inability of bone marrow to compensate the premature destruction of red blood cells.

We study 1,016 people who have Microangiopathic haemolytic anaemia. The information that eHealthMe analyzes includes:

- Medications that treat Microangiopathic haemolytic anaemia and their effectiveness
- 99 drugs that are associated with Microangiopathic haemolytic anaemia


Number of reports submitted per year:

Microangiopathic haemolytic anaemia: 1,016 reports.

All the drugs that are associated with Microangiopathic haemolytic anaemia:

Do you take any medication?

- You can use our AI-powered tools to monitor drug safety and effectiveness.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

How we gather our data?

Healthcare data is obtained from a number of sources including the Food and Drug Administration (FDA). This information is aggregated and used to produce personalized reports that patients can reference. Browse all conditions on eHealthMe.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.